Related references
Note: Only part of the references are listed.Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients
M. Effenberger et al.
JOURNAL OF CROHNS & COLITIS (2021)
Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease
Femke Crouwel et al.
JOURNAL OF CROHNS & COLITIS (2021)
The microbiome in inflammatory bowel diseases: from pathogenesis to therapy
Sheng Liu et al.
PROTEIN & CELL (2021)
Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review
Maria Manuela Estevinho et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Javier P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2020)
Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients
Marianna Lucafo et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
The microbiome and inflammatory bowel disease
Kerri L. Glassner et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Changes in the Intestinal Microbiota Are Seen Following Treatment with Infliximab in Children with Crohn's Disease
Kinga Kowalska-Duplaga et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems
Yu Xu et al.
FRONTIERS IN MICROBIOLOGY (2020)
Label or Concept - What is a Pathobiont?
Lara Jochum et al.
TRENDS IN MICROBIOLOGY (2020)
The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases
Nikolas Dovrolis et al.
MICROORGANISMS (2020)
Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More
Benjamin Misselwitz et al.
DIGESTION (2020)
Inflammatory Bowel Diseases: It's Time for the Adenosine System
Luca Antonioli et al.
FRONTIERS IN IMMUNOLOGY (2020)
Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle
Gyeol Seong et al.
MICROORGANISMS (2020)
A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague-Dawley Rats
Marine P. M. Letertre et al.
JOURNAL OF PROTEOME RESEARCH (2020)
Predicting Response to Vedolizumab in Inflammatory Bowel Disease
Joseph Meserve et al.
FRONTIERS IN MEDICINE (2020)
Medical Management of Crohn's Disease
Ajay K. Gade et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2020)
Role of intestinal microbiota and metabolites in inflammatory bowel disease
Li-Na Dong et al.
CHINESE MEDICAL JOURNAL (2019)
Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases
Konrad Aden et al.
GASTROENTEROLOGY (2019)
Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
Cristiano Pagnini et al.
FRONTIERS IN PHARMACOLOGY (2019)
Human Gut-Associated Natural Killer Cells in Health and Disease
Alessandro Poggi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Microbiota and mucosal defense in IBD: an update
Eduard F. Stange et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease
Davide Giuseppe Ribaldone et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease
Fabio Salvatore Macaluso et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease
Todd Atherly et al.
PLOS ONE (2019)
Medical management of Crohn's disease: state of the art and future perspectives
Fabio Salvatore Macaluso
ITALIAN JOURNAL OF MEDICINE (2019)
The role of gut microbiota in the modulation of drug action: a focus on some clinically significant issues
Diego Curro
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease
M. T. Tang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
A. Barre et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Therapeutic role of methotrexate in pediatric Crohn's disease
Zlatko Djuric et al.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES (2018)
Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways
Jesus K. Yamamoto-Furusho
CURRENT OPINION IN GASTROENTEROLOGY (2018)
Current, experimental, and future treatments in inflammatory bowel disease: a clinical review
Christian L. Hvas et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2018)
A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease
Pedro Goncalves et al.
INFLAMMATORY BOWEL DISEASES (2018)
Evidence-based clinical practice guidelines for inflammatory bowel disease
Katsuyoshi Matsuoka et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Establishing a mucosal gut microbial community in vitro using an artificial simulator
LinShu Liu et al.
PLOS ONE (2018)
Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients
Matthew K. Doherty et al.
MBIO (2018)
Immunotherapy in inflammatory bowel disease: Novel and emerging treatments
Ignacio Catalan-Serra et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis
Jun Xu et al.
FRONTIERS IN MICROBIOLOGY (2018)
Induction and Amelioration of Methotrexate-Induced Gastrointestinal Toxicity are Related to Immune Response and Gut Microbiota
Bailing Zhou et al.
EBIOMEDICINE (2018)
Evaluating the clinical importance of bacterial degradation of therapeutic agents in the lower intestine of adults using adult fecal material
Maria Vertzoni et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity
Shiying Zhang et al.
JOURNAL OF ANTIBIOTICS (2018)
The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease
Tao Zuo et al.
FRONTIERS IN MICROBIOLOGY (2018)
Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
Sheng Zhang Lim et al.
FRONTIERS IN PHARMACOLOGY (2018)
Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis
Linda Chia-Hui Yu
JOURNAL OF BIOMEDICAL SCIENCE (2018)
Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
Akihiro Koga et al.
INTESTINAL RESEARCH (2018)
Natalizumab for induction of remission in Crohn's disease
Seana M. L. Nelson et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis
Ellie Sayers et al.
AIMS MICROBIOLOGY (2018)
Gut microbiota in the pathogenesis of inflammatory bowel disease
Atsushi Nishida et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2018)
Role of gut microbiota in intestinal wound healing and barrier function
Ashfaqul Alam et al.
TISSUE BARRIERS (2018)
Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis
Stefanos Bonovas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism
I. Oancea et al.
GUT (2017)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
The safety of non-biological treatments in Ulcerative Colitis
Edoardo Troncone et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease
H. Matthew Cohn et al.
INFLAMMATORY BOWEL DISEASES (2017)
Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology
Karen Dubois-Camacho et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric Microbes
Fang Liu et al.
FRONTIERS IN MICROBIOLOGY (2017)
Host-microbial Cross-talk in Inflammatory Bowel Disease
Hiroko Nagao-Kitamoto et al.
IMMUNE NETWORK (2017)
Inflammatory disease caused by intestinal pathobionts
Ellen L. Zechner
CURRENT OPINION IN MICROBIOLOGY (2017)
Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases
Ashwin N. Ananthakrishnan et al.
CELL HOST & MICROBE (2017)
Role of intestinal microbiota and metabolites on gut homeostasis and human diseases
Lan Lin et al.
BMC IMMUNOLOGY (2017)
Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease
Mehmet Coskun et al.
CLINICAL PHARMACOKINETICS (2016)
The influence of gut microbiota on drugmetabolismand toxicity
Houkai Li et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Functions of innate immune cells and commensal bacteria in gut homeostasis
Hisako Kayama et al.
JOURNAL OF BIOCHEMISTRY (2016)
The glucocorticoid budesonide has protective and deleterious effects in experimental colitis in mice
Borja Ocon et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Antimicrobial peptides
Ling-juan Zhang et al.
CURRENT BIOLOGY (2016)
Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases
Hans H. Herfarth et al.
INFLAMMATORY BOWEL DISEASES (2016)
Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition
Maria K. Magnusson et al.
JOURNAL OF CROHNS & COLITIS (2016)
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Tim Wyant et al.
JOURNAL OF CROHNS & COLITIS (2016)
Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease
Clare Moore et al.
JOURNAL OF CROHNS & COLITIS (2016)
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Alon D. Levin et al.
JOURNAL OF CROHNS & COLITIS (2016)
Microbial metabolism of thiopurines: A method to measure thioguanine nucleotides
Ramya Movva et al.
JOURNAL OF MICROBIOLOGICAL METHODS (2016)
Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease
Kelly A. Shaw et al.
GENOME MEDICINE (2016)
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions
Stephen M. Vindigni et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
The role of the gut microbiome in the healthy adult status
Valeria D'Argenio et al.
CLINICA CHIMICA ACTA (2015)
Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases
Edmond Y. Huang et al.
INFLAMMATORY BOWEL DISEASES (2015)
Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn's Disease
David Busquets et al.
JOURNAL OF CROHNS & COLITIS (2015)
Altered Fecal Microbiota in Paediatric Inflammatory Bowel Disease
Johanna Maukonen et al.
JOURNAL OF CROHNS & COLITIS (2015)
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
Giovanni Cammarota et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy
Rahil Dahlen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
New biologic therapeutics for ulcerative colitis and Crohn's disease
Shilan Mozaffari et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Aleksandar D. Kostic et al.
GASTROENTEROLOGY (2014)
Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission
Michelle G. Rooks et al.
ISME JOURNAL (2014)
Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics
Rachel N. Carmody et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
On the Colonic Bacterial Metabolism of Azo-Bonded Prodrugs of 5-Aminosalicylic Acid
Tiago Sousa et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Fecal Microbial Composition of Ulcerative Colitis and Crohn's Disease Patients in Remission and Subsequent Exacerbation
Edgar S. Wills et al.
PLOS ONE (2014)
Effect of Oral Administration of Metronidazole or Prednisolone on Fecal Microbiota in Dogs
Hirotaka Igarashi et al.
PLOS ONE (2014)
Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years?
Georgina L. Hold et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Dysbiosis in the inflamed intestine Chance favors the prepared microbe
Sebastian E. Winter et al.
GUT MICROBES (2014)
The effect of gut microbiota on drug metabolism
Mi Jeong Kang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
Xavier Hebuterne et al.
GUT (2013)
Colonic bacterial metabolism of corticosteroids
Vipul Yadav et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis
Lionel Rigottier-Gois
ISME JOURNAL (2013)
Management of Active Crohn Disease
Adam S. Cheifetz
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
The possible effects of mesalazine on the intestinal microbiota
L. Xue et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
New Drug Therapies on the Horizon for IBD
Clementine Perrier et al.
DIGESTIVE DISEASES (2012)
Susceptibility of glucocorticoids to colonic metabolism and pharmacologic intervention in the metabolism: implication for therapeutic activity of colon-specific glucocorticoid 21-sulfate sodium at the target site
Hyesik Kong et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2012)
Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics
Nina A. Hering et al.
JOURNAL OF PHYSIOLOGY-LONDON (2012)
Folate and DNA Methylation: A Review of Molecular Mechanisms and the Evidence for Folate's Role
Krista S. Crider et al.
ADVANCES IN NUTRITION (2012)
Epithelial antimicrobial defence of the skin and intestine
Richard L. Gallo et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Host-microbiota interactions in inflammatory bowel disease
Charles O. Elson et al.
GUT MICROBES (2012)
Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease
Alan W. Walker et al.
BMC MICROBIOLOGY (2011)
Disease Phenotype and Genotype Are Associated with Shifts in Intestinal-associated Microbiota in Inflammatory Bowel Diseases
Daniel N. Frank et al.
INFLAMMATORY BOWEL DISEASES (2011)
The intestinal microbiota in inflammatory bowel diseases: time to connect with the host
Harry Sokol et al.
CURRENT OPINION IN GASTROENTEROLOGY (2010)
The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models
Sandra Nell et al.
NATURE REVIEWS MICROBIOLOGY (2010)
Thiopurine pathway
Gianluigi Zaza et al.
PHARMACOGENETICS AND GENOMICS (2010)
Measurement of Erythrocyte Methotrexate Polyglutamate Levels: Ready for Clinical Use in Rheumatoid Arthritis?
Maria I. Danila et al.
Current Rheumatology Reports (2010)
Adenosine: An immune modulator of inflammatory bowel diseases
Jeff Huaqing Ye et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Biological therapy of inflammatory bowel disease
Danuta Owczarek et al.
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE (2009)
The gut microbiota shapes intestinal immune responses during health and disease
June L. Round et al.
NATURE REVIEWS IMMUNOLOGY (2009)
The gastrointestinal microbiota as a site for the biotransformation of drugs
Tiago Sousa et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro
Sung Jae Shin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn's disease
B. W. Behm et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2008)
Traditional corticosteroids for induction of remission in Crohn's disease
E. Benchimol et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2008)
Dual-association of gnotobiotic IL-10-/- mice vith 2 nonpathogenic commensal bacteria induces aggressive pancolitis
Sandra C. Kim et al.
INFLAMMATORY BOWEL DISEASES (2007)
On the Action of 5-Amino-Salicylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosis
Robert J. Greenstein et al.
PLOS ONE (2007)
On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosis
Robert J. Greenstein et al.
PLOS ONE (2007)
Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis
Alexander Swidsinski et al.
INFLAMMATORY BOWEL DISEASES (2007)
Bacteria in the pathogenesis of inflammatory bowel disease
Sreedhar Subramanian et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2006)
Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: Their mechanisms of action and role in the treatment of IBD
JM van Dieren et al.
INFLAMMATORY BOWEL DISEASES (2006)
Review article: thiopurines in inflammatory bowel disease
L. J. J. Derijks et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ
C Rousseaux et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Tertiary structure of thiopurine methyltransferase from Pseudomonas syringae, a bacterial orthologue of a polymorphic, drug-metabolizing enzyme
T Scheuermann et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Drug methylation in cancer therapy: lessons from the TPMT polymorphism
E Krynetski et al.
ONCOGENE (2003)
The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria
LM Edmond et al.
INFLAMMATORY BOWEL DISEASES (2003)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Mucosal flora in inflammatory bowel disease
A Swidsinski et al.
GASTROENTEROLOGY (2002)
Identification and functional characterization of arylamine N-acetyltransferases in eubacteria:: Evidence for highly selective acetylation of 5-aminosalicylic acid
C Deloménie et al.
JOURNAL OF BACTERIOLOGY (2001)
Molecular analysis of commensal host-microbial relations hips in the intestine
LV Hooper et al.
SCIENCE (2001)
Share Paper
